As a cardiologist, Dr. Marc Litt has plenty of arrows in his quiver for patients with heart disease: Medications that thin blood. Drug-coated stents that widen blocked arteries. Implants that replace damaged valves in minimally invasive surgery.

But when the 63-year-old physician was diagnosed with ALS in March 2019 at Massachusetts General Hospital, he was dismayed to see how little medicine had to offer him. Despite at least 50 clinical trials of potential drugs since 1995, only two drugs have been approved to slow the progression of the deadly degenerative neurological disease, and neither is all that effective.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy